Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus ETHRIL 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus ETHRIL 500.
ERYTHROMYCIN AND BENZOYL PEROXIDE vs ETHRIL 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
Acetaminophen (paracetamol) is a central analgesic and antipyretic agent whose exact mechanism is not fully understood but is thought to involve inhibition of cyclooxygenase (COX) enzymes in the brain, primarily COX-2, and activation of descending serotonergic pathways. It has weak peripheral anti-inflammatory activity.
Topical: Apply a thin layer to affected areas once daily in the evening.
500 mg orally every 6 hours as needed for pain. Maximum daily dose: 2000 mg.
None Documented
None Documented
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 6-12 hours in hepatic impairment or overdose.
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Renal excretion of unchanged drug and glucuronide conjugate accounts for 90-95% of elimination; biliary/fecal elimination accounts for 5-10%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic